Who are ABX464 Single dose's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ABX464.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abx464-single-dose.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ABX464 Single dose — Competitive Intelligence Brief

ABX464 Single dose (ABX464 Single dose) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RNA splicing modulator. Area: Infectious Disease.

phase 1 RNA splicing modulator RNA splicing process Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

ABX464 Single dose (ABX464 Single dose) — Abivax S.A.. ABX464 is a small molecule that modulates the RNA splicing process to inhibit HIV replication.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ABX464 Single dose TARGET	ABX464 Single dose	Abivax S.A.	phase 1	RNA splicing modulator	RNA splicing process
ABX464	ABX464	Abivax S.A.	phase 3	RNA splicing modulator	RNA splicing machinery (non-specific modulator)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RNA splicing modulator class)

Abivax S.A. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABX464 Single dose — Competitive Intelligence Brief. https://druglandscape.com/ci/abx464-single-dose. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab